
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is a clinical-stage biopharmaceutical company that is focusing on developing innovative treatments for diseases in immunology, inflammation, and oncology areas. The company has a promising pipeline product, Seralutinib, which is addressing a high unmet need in the pulmonary arterial hypertension (PAH) market. The recent updates from the company, including a positive Type B meeting with the FDA and favorable CT FRI data, reaffirm the company's strong regulatory and clinical narrative. Additionally, the recent completion of its convertible note exchange offer reflects creditors' confidence in the company's ability to successfully execute its regulatory plans. While there are still risks and uncertainties, the current valuation does not fully factor in the potential approval and launch of Seralutinib, and therefore, this analyst maintains a positive outlook on Gossamer Bio's stock.
Bears say
Gossamer Bio is expected to face challenges in the development, commercialization, and reimbursement of their primary product candidate, seralutinib, as well as potential dilution risks and pricing uncertainties. Additionally, the reversible and monitorable safety profile of seralutinib is not enough to offset concerns over its failure to meet primary endpoint in PAH trials and potentially limited efficacy in PH-ILD. Overall, the company's market cap of $1.1 billion seems overvalued.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares